Please upgrade your browser.
Alpha Tau Omega of the University of California Santa Barbara presents All Sorority Volleyball Tournament 2008
Volleyball tournament raises thousands for kidney cancer!!
SGN-75 is an antibody-drug conjugate (ADC) that has demonstrated potent antitumor activity at well-tolerated doses in preclinical models of renal cell cancer.
But study reveals wide variations between countries.
Drugs hailed as breakthrough treatments for cancer, Britain's biggest cause of death, may be less effective and cause more harm than suspected, they said.
A little biotech company, Antigenics (AGEN), announced that Russia has approved its kidney cancer drug, Oncophage. It's the first so-called therapeutic cancer vaccine to win full-out approval anywhere in the world.
New Clinical Data on AVEO Pharmaceuticals' Investigational Triple VEGFR Small Molecule Inhibitor AV-951 to be Presented at AACR Annual Meeting
AV-951 is a novel, highly potent and specific inhibitor of VEGF receptors 1, 2 and 3. Angiogenesis inhibition has demonstrated benefit for patients with a wide range of cancer types, including renal cell carcinoma.
Thallion Pharmaceuticals Inc. completed patient enrollment for the Phase II trial using the new continuous intravenous regimen of TLN-232 (formerly CAP-232) in refractory renal cell carcinoma patients.
Deb Maskens is at the U.S. National Institutes of Health (NIH) in Bethesda, Maryland, for a diagnosis she can't get at home.
Survey confirms dire shortage of specialists is a significant and ongoing issue for patients in all provinces and territories.
Company will implement the free patient assistance programme by partnering with two leading cancer hospitals in Nepal.
|Powered by NeonCRM|